Dr. Timos Papagatsias’ Post

Thoughts on this? >> Pfizer and BioNTech say GSK's Covid patent suit is 'groundless' >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #productmarketing

Thoughts on this? >> GSK accuses Pfizer and BioNTech of mRNA patent infringement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical

Stay ahead in the pharma industry with our comprehensive DrugPatentWatch Week in Review. Get insights into the latest patent expirations, new drug approvals, and market trends. Equip yourself with the knowledge to make informed decisions. #PharmaIndustry #PatentExpiration #DrugApprovals #WeeklyUpdate

Thoughts on this? >> Liquidia wins with Supreme Court decision to not review Yutrepia-Tyvaso patent battle >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #biotech #pharma

Thoughts on this? >> Liquidia wins with Supreme Court decision to not review Yutrepia-Tyvaso patent battle >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #pharma #healthcare

The FDA 505b2 Pathway was born out of the Hatch-Waxman Amendments in 1984, and has completely revamped the drug approval process. It's like a secret weapon that allows companies to tap into third-party studies, saving both application time and costs. This 505b2 Pathway is no ordinary route; it's a hybrid of the 505b1 and 505j. Imagine the possibility of bidding farewell to nonclinical studies, reducing risks, enjoying a streamlined application process, and faster development: https://lnkd.in/dYfY8uSq #pharmaceutical #3dprinting #3dprintingtechnology #medicalinnovation #medicaltechnology #medicaltech

💼 Legal Update: Moderna vs. Pfizer/BioNTech Patent Dispute 💼 The UK High Court has delivered a mixed verdict in the ongoing patent dispute between Moderna and its competitors, Pfizer and BioNTech. 📌 The court invalidated Moderna’s EP 3 718 565 patent but upheld the validity and infringement of EP 3 590 949. This decision requires Pfizer and BioNTech to compensate Moderna for using their patented technology after March 7, 2022. 🏆 📌 This ruling is part of a broader series of global lawsuits initiated by Moderna in 2022, covering multiple countries, including Germany, the Netherlands, Belgium, Ireland, and the UK. The core of the dispute revolves around Moderna’s RNA technology and respiratory virus vaccine patents. While the High Court's decision is subject to #appeal, it underscores the critical importance of protecting intellectual property in the pharmaceutical industry. Both parties have expressed intentions to appeal some aspects of the judgment. Stay tuned for further updates as this case progresses! #Moderna #Pfizer #BioNTech #PatentLaw #Pharmaceuticals #Innovation #LegalNews

A strong #IP search strategy upfront can set your #pharmaceutical substance up for success. Register for our July 24 webinar with Managing IP and learn how: https://ow.ly/hor350SuIYE

A recent Federal Circuit decision indicates that public statements by a generic drug manufacturer can be relied upon to show induced infringement of method of treatment patents, even where the generic uses a "skinny label." Click below to download our Commentary, which analyzes the decision and its implications for drug manufacturers. Anthony Insogna Sarah Geers Matt Hertko Andrea Jeffries Jason Winchester #intellectualproperty #patentlaw #pharmaceuticals

Our latest report on Drug Repurposing & Repositioning in Europe is out now! 🎉 Download your copy now and unlock the potential of drug repurposing. 💼 https://lnkd.in/ecptm4Sa In collaboration with industry experts from NLO | European patent and trademark attorneys, 3D-PharmXchange, and the REPO4EU consortium, we've delved deep into the regulatory framework and patent opportunities surrounding drug repurposing. 💡 Covering major topics such as off-patent products and new indications, our report provides invaluable insights into protecting the results of repurposing programs. 💊 Discover effective strategies to prevent others from benefiting from new indications, navigate regulatory challenges, and ensure proper alignment between clinical trials and IP filings. 🚀 Whether you're aiming to benefit patients or create economic value, our report highlights the key to success: staying in control of your program's results by establishing exclusivity. 💼 Barend Bouma Jaap Mannaerts Bianca Pauly #DrugRepurposing #IPStrategy #Pharmaceuticals #RegulatoryFramework #PatentOpportunities